Asset
MITAPIVAT
AGIOS PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (23)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05610657 | phase1 | completed | 2023-01-10 | 2023-07-21 | Agios Pharmaceuticals, Inc. | A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function |
| NCT02108106 | phase1 | completed | 2014-03-01 | 2014-08-01 | Agios Pharmaceuticals, Inc. | A Phase I Study of AG-348 in Healthy Volunteers |
| NCT02149966 | phase1 | completed | 2014-05-01 | 2014-11-01 | Agios Pharmaceuticals, Inc. | A Phase I Study of AG-348 in Healthy Volunteers |
| NCT03559699 | phase3 | completed | 2018-06-26 | 2020-11-12 | Agios Pharmaceuticals, Inc. | A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) |
| NCT05031780 | phase2_3 | active_not_recruiting | 2022-02-11 | 2025-10-30 | Agios Pharmaceuticals, Inc. | A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) |
FDA applications (0)
This company has no applications containing this asset.